1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Canada >
  5. British Columbia >
  6. Precigen Acquires Okanagan Specialty Fruits

M&A Deal Summary

Precigen Acquires Okanagan Specialty Fruits

On April 20, 2015, Precigen acquired life science company Okanagan Specialty Fruits for 31M USD

Acquisition Highlights
  • This is Precigen’s 7th transaction in the Life Science sector.
  • This is Precigen’s 4th largest (disclosed) transaction.
  • This is Precigen’s 1st transaction in Canada.
  • This is Precigen’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2015-04-20
Target Okanagan Specialty Fruits
Sector Life Science
Buyer(s) Precigen
Deal Type Add-on Acquisition
Deal Value 31M USD

Target

Okanagan Specialty Fruits

Summerland, British Columbia, Canada
Okanagan Specialty Fruits, Inc. is a agriculture biotechnology company. It specializes in developing tree fruit varieties with novel attributes.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Precigen

Germantown, Maryland, United States
Category Company
Founded 1998
Sector Life Science
Employees143
Revenue 4M USD (2024)
DESCRIPTION

Precigen provides biologically based products and processes that improve the quality of life and health of the planet. The science underlying these products is known as synthetic biology – an engineered approach to the field of biology. Precigen was founded in 1998 and is based in Germantown, Maryland.

DEAL STATS #
Overall 7 of 10
Sector: Life Science M&A 7 of 9
Type: Add-on Acquisition M&A Deals 5 of 7
State: British Columbia M&A 1 of 1
Country: Canada M&A 1 of 1
Year: 2015 M&A 3 of 4
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-13 ActoGeniX NV

Zwijnaarde, Belgium

ActoGenix develops therapies, based on its patented TopAct™ technology platform, which address major diseases requiring intensive medical care, including gastrointestinal problems, auto-immunity diseases, allergies and metabolic disorders. TopAct™ uses micro-organisms for the oral administration of proteins. ActoGeniX’s first product – for treating Crohn’s disease - has already been successfully tested on patients.

Buy $60M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-10 Oxitec

Oxford, United Kingdom

Oxitec Ltd. is a provider of biological insect control solutions. Oxitec Ltd. was founded in 2002 and is based in Oxford, UK.

Buy $160M
Mergr

Solution for

Product

Company

Legal